Cargando…
Ribosomal Antibiotics: Contemporary Challenges
Most ribosomal antibiotics obstruct distinct ribosomal functions. In selected cases, in addition to paralyzing vital ribosomal tasks, some ribosomal antibiotics are involved in cellular regulation. Owing to the global rapid increase in the appearance of multi-drug resistance in pathogenic bacterial...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5039520/ https://www.ncbi.nlm.nih.gov/pubmed/27367739 http://dx.doi.org/10.3390/antibiotics5030024 |
_version_ | 1782456073758703616 |
---|---|
author | Auerbach-Nevo, Tamar Baram, David Bashan, Anat Belousoff, Matthew Breiner, Elinor Davidovich, Chen Cimicata, Giuseppe Eyal, Zohar Halfon, Yehuda Krupkin, Miri Matzov, Donna Metz, Markus Rufayda, Mruwat Peretz, Moshe Pick, Ophir Pyetan, Erez Rozenberg, Haim Shalev-Benami, Moran Wekselman, Itai Zarivach, Raz Zimmerman, Ella Assis, Nofar Bloch, Joel Israeli, Hadar Kalaora, Rinat Lim, Lisha Sade-Falk, Ofir Shapira, Tal Taha-Salaime, Leena Tang, Hua Yonath, Ada |
author_facet | Auerbach-Nevo, Tamar Baram, David Bashan, Anat Belousoff, Matthew Breiner, Elinor Davidovich, Chen Cimicata, Giuseppe Eyal, Zohar Halfon, Yehuda Krupkin, Miri Matzov, Donna Metz, Markus Rufayda, Mruwat Peretz, Moshe Pick, Ophir Pyetan, Erez Rozenberg, Haim Shalev-Benami, Moran Wekselman, Itai Zarivach, Raz Zimmerman, Ella Assis, Nofar Bloch, Joel Israeli, Hadar Kalaora, Rinat Lim, Lisha Sade-Falk, Ofir Shapira, Tal Taha-Salaime, Leena Tang, Hua Yonath, Ada |
author_sort | Auerbach-Nevo, Tamar |
collection | PubMed |
description | Most ribosomal antibiotics obstruct distinct ribosomal functions. In selected cases, in addition to paralyzing vital ribosomal tasks, some ribosomal antibiotics are involved in cellular regulation. Owing to the global rapid increase in the appearance of multi-drug resistance in pathogenic bacterial strains, and to the extremely slow progress in developing new antibiotics worldwide, it seems that, in addition to the traditional attempts at improving current antibiotics and the intensive screening for additional natural compounds, this field should undergo substantial conceptual revision. Here, we highlight several contemporary issues, including challenging the common preference of broad-range antibiotics; the marginal attention to alterations in the microbiome population resulting from antibiotics usage, and the insufficient awareness of ecological and environmental aspects of antibiotics usage. We also highlight recent advances in the identification of species-specific structural motifs that may be exploited for the design and the creation of novel, environmental friendly, degradable, antibiotic types, with a better distinction between pathogens and useful bacterial species in the microbiome. Thus, these studies are leading towards the design of “pathogen-specific antibiotics,” in contrast to the current preference of broad range antibiotics, partially because it requires significant efforts in speeding up the discovery of the unique species motifs as well as the clinical pathogen identification. |
format | Online Article Text |
id | pubmed-5039520 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-50395202016-10-04 Ribosomal Antibiotics: Contemporary Challenges Auerbach-Nevo, Tamar Baram, David Bashan, Anat Belousoff, Matthew Breiner, Elinor Davidovich, Chen Cimicata, Giuseppe Eyal, Zohar Halfon, Yehuda Krupkin, Miri Matzov, Donna Metz, Markus Rufayda, Mruwat Peretz, Moshe Pick, Ophir Pyetan, Erez Rozenberg, Haim Shalev-Benami, Moran Wekselman, Itai Zarivach, Raz Zimmerman, Ella Assis, Nofar Bloch, Joel Israeli, Hadar Kalaora, Rinat Lim, Lisha Sade-Falk, Ofir Shapira, Tal Taha-Salaime, Leena Tang, Hua Yonath, Ada Antibiotics (Basel) Review Most ribosomal antibiotics obstruct distinct ribosomal functions. In selected cases, in addition to paralyzing vital ribosomal tasks, some ribosomal antibiotics are involved in cellular regulation. Owing to the global rapid increase in the appearance of multi-drug resistance in pathogenic bacterial strains, and to the extremely slow progress in developing new antibiotics worldwide, it seems that, in addition to the traditional attempts at improving current antibiotics and the intensive screening for additional natural compounds, this field should undergo substantial conceptual revision. Here, we highlight several contemporary issues, including challenging the common preference of broad-range antibiotics; the marginal attention to alterations in the microbiome population resulting from antibiotics usage, and the insufficient awareness of ecological and environmental aspects of antibiotics usage. We also highlight recent advances in the identification of species-specific structural motifs that may be exploited for the design and the creation of novel, environmental friendly, degradable, antibiotic types, with a better distinction between pathogens and useful bacterial species in the microbiome. Thus, these studies are leading towards the design of “pathogen-specific antibiotics,” in contrast to the current preference of broad range antibiotics, partially because it requires significant efforts in speeding up the discovery of the unique species motifs as well as the clinical pathogen identification. MDPI 2016-06-29 /pmc/articles/PMC5039520/ /pubmed/27367739 http://dx.doi.org/10.3390/antibiotics5030024 Text en © 2016 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Auerbach-Nevo, Tamar Baram, David Bashan, Anat Belousoff, Matthew Breiner, Elinor Davidovich, Chen Cimicata, Giuseppe Eyal, Zohar Halfon, Yehuda Krupkin, Miri Matzov, Donna Metz, Markus Rufayda, Mruwat Peretz, Moshe Pick, Ophir Pyetan, Erez Rozenberg, Haim Shalev-Benami, Moran Wekselman, Itai Zarivach, Raz Zimmerman, Ella Assis, Nofar Bloch, Joel Israeli, Hadar Kalaora, Rinat Lim, Lisha Sade-Falk, Ofir Shapira, Tal Taha-Salaime, Leena Tang, Hua Yonath, Ada Ribosomal Antibiotics: Contemporary Challenges |
title | Ribosomal Antibiotics: Contemporary Challenges |
title_full | Ribosomal Antibiotics: Contemporary Challenges |
title_fullStr | Ribosomal Antibiotics: Contemporary Challenges |
title_full_unstemmed | Ribosomal Antibiotics: Contemporary Challenges |
title_short | Ribosomal Antibiotics: Contemporary Challenges |
title_sort | ribosomal antibiotics: contemporary challenges |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5039520/ https://www.ncbi.nlm.nih.gov/pubmed/27367739 http://dx.doi.org/10.3390/antibiotics5030024 |
work_keys_str_mv | AT auerbachnevotamar ribosomalantibioticscontemporarychallenges AT baramdavid ribosomalantibioticscontemporarychallenges AT bashananat ribosomalantibioticscontemporarychallenges AT belousoffmatthew ribosomalantibioticscontemporarychallenges AT breinerelinor ribosomalantibioticscontemporarychallenges AT davidovichchen ribosomalantibioticscontemporarychallenges AT cimicatagiuseppe ribosomalantibioticscontemporarychallenges AT eyalzohar ribosomalantibioticscontemporarychallenges AT halfonyehuda ribosomalantibioticscontemporarychallenges AT krupkinmiri ribosomalantibioticscontemporarychallenges AT matzovdonna ribosomalantibioticscontemporarychallenges AT metzmarkus ribosomalantibioticscontemporarychallenges AT rufaydamruwat ribosomalantibioticscontemporarychallenges AT peretzmoshe ribosomalantibioticscontemporarychallenges AT pickophir ribosomalantibioticscontemporarychallenges AT pyetanerez ribosomalantibioticscontemporarychallenges AT rozenberghaim ribosomalantibioticscontemporarychallenges AT shalevbenamimoran ribosomalantibioticscontemporarychallenges AT wekselmanitai ribosomalantibioticscontemporarychallenges AT zarivachraz ribosomalantibioticscontemporarychallenges AT zimmermanella ribosomalantibioticscontemporarychallenges AT assisnofar ribosomalantibioticscontemporarychallenges AT blochjoel ribosomalantibioticscontemporarychallenges AT israelihadar ribosomalantibioticscontemporarychallenges AT kalaorarinat ribosomalantibioticscontemporarychallenges AT limlisha ribosomalantibioticscontemporarychallenges AT sadefalkofir ribosomalantibioticscontemporarychallenges AT shapiratal ribosomalantibioticscontemporarychallenges AT tahasalaimeleena ribosomalantibioticscontemporarychallenges AT tanghua ribosomalantibioticscontemporarychallenges AT yonathada ribosomalantibioticscontemporarychallenges |